Adalimumab in Plaque psoriasis: ISRCTN18260393 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Not yet recruiting
Recruitment status
310
Planned enrollment
2029-10-31
Primary-completion proxy
Executive view
ISRCTN18260393 evaluates Adalimumab in Plaque psoriasis. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is United Kingdom. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ISRCTN18260393 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Plaque psoriasis landscape. Drug & Asset MCP drug_fetch was queried for Adalimumab, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| ISRCTN18260393 | Adalimumab | Phase 3 / Not yet recruiting | Sponsor not reported | United Kingdom | 2029-10-31 | |
| NCT07746479 | Lecankitug | Phase 3 / Completed | Livzon Pharmaceutical Group, Inc. | China | PASI100 response rate At week 12 | 2026-01-26 |
| NCT07744191 | Clopidogrel Bisulfate | Phase 4 / Not yet recruiting | NYU Langone Health | United States | Mean change in the composite endothelial pro-inflammatory transcript expression Baseline, Follow-up Visit 1 (Week 4) | 2031-09-01 |
| ACTRN12626000951358 | Semaglutide (Novo Nordisk) | Not Applicable / Not yet recruiting | Bayside Health | Australia | Timing not reported | |
| NCT07733089 | ZP-9830 | Phase 1 / Recruiting | Zealand Pharma A/S | Netherlands | Number of Treatment Emergent Adverse Events (TEAEs) From baseline (Day 1, predose) to follow-up (Day 85) | 2027-04-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
ISRCTN18260393 is a Phase 3, not yet recruiting study with 310 planned participants. Allocation is Randomized controlled trial, masking is Blinded (masking used), and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: Primary clinical end point: The proportion of participants achieving a 75% improvement in their psoriasis area and severity score (PASI 75) at 16 weeks compared to baseline Primary economic end point: Incremental cost per quality-adjusted life year (QALY) gained at 24 weeks, based on EQ-5D-5L collected at baseline, 16 and 24 weeks and Service Use Questionnaire (SUQ) collected at baseline and 24 weeks.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 310 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Methotrexate Sodium as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Plaque psoriasis. These records do not establish direct evidence for ISRCTN18260393 unless the registration number matches.
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41769731/
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis' Roflumilast Cream 0.3% to Arcutis's Zoryve™ (Roflumilast Cream 0.3%) Cream and…
Phase 3; n=416; IGA = 78 Participants ; IGA = 79 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05763082
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Adalimumab is indexed as Monoclonal antibody with TNF-α biology and a global stage of Approved. The asset profile lists AbbVie, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Adalimumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: ISRCTN18260393
Protocol source: https://www.isrctn.com/ISRCTN18260393
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Adalimumab in Plaque psoriasis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and 2029-10-31 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
